Blinatumomab for treatment of children with acute lymphoblastic leukaemia in Hong Kong: A cost‐effectiveness analysis
Mingjun Rui, Yin Ting Cheung, Hui Zhang, Qiran Wei, Yingcheng Wang, Jiaqi Shi, Chi Kong Li, Joyce H. S. You · 2026
Read Blinatumomab for treatment of children with acute lymphoblastic leukaemia in Hong Kong: A cost‐effectiveness analysis by Mingjun Rui, Yin Ting Cheung, Hui Zhang, Qiran Wei, Yingcheng Wang, Jiaqi Shi, Chi Kong Li, Joyce H. S. You (2026) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/pmc-13570225.txt.
Description
Mingjun Rui and colleagues modelled whether adding blinatumomab to chemotherapy pays off for Hong Kong children with standard-risk B-cell leukaemia, publishing the cost-effectiveness analysis in 2026. The immune drug improved disease-free survival in a large trial, but its value from a public payer's view was untested. The team built a ten-year Markov model for average- and high-relapse-risk children, comparing chemotherapy alone with blinatumomab added first-line or second-line.
Both blinatumomab strategies fell below Hong Kong's willingness-to-pay threshold, with first-line use preferred in most probabilistic simulations. Drug cost and survival gains drove the results most. The authors conclude first-line blinatumomab appears cost-effective for newly diagnosed standard-risk paediatric B-cell leukaemia in this setting.
Catalog record
| CREATOR | Mingjun Rui, Yin Ting Cheung, Hui Zhang, Qiran Wei, Yingcheng Wang, Jiaqi Shi, Chi Kong Li, Joyce H. S. You |
|---|---|
| YEAR | 2026 |
| COLLECTION | PAPERS |
| FORMAT | TXT |
| FILE SIZE | 37 KB |
| VERSION | 1.0 |
| LICENSE | CC BY 4.0 |
| RIGHTS | CC BY |
| SOURCE | Europe PMC |